Diabeter Research

News in diabetes care!: A recent study conducted at the Diabeter clinic in the Netherlands has shown promising results for automated insulin delivery in managing #type1diabetes. This real-world study, co-authored by Pim Dekker and Henk-Jan Aanstoot from #Diabeter followed people with type 1 diabetes (PWDs) using the #MM780G system for 12 months and found significant improvements in blood sugar control across all age groups. This research underscores the potential of advanced hybrid closed-loop systems to improve the lives of PWDs. To learn more about this study, visit the Diabeter Research website: https://lnkd.in/ejBk5MgN #diabetes #diabetestechnology #T1D #research #healthcare #insulindelivery

This publication co-authored by @TheoSas from @Diabeter assessed cause-specific mortality rates among Dutch people with #diabetes, using the Dutch diabetes registry #DPARD. They found relatively high mortality, associating with, amongst others, weight and renal failure.   https://lnkd.in/emRqcdqJ   #Diabetesregistry #DPARD #type1diabetes #T1D #type2diabetes #T2D #diabetescomplications #diabetesoutcomes

This publication co-authored by @TheoSas from @Diabeter compared Dutch quality indicators from the #DPARD #diabetes registry with indicators from diabetes registries around the world. The authors describe much variation in the use of #quality indicators. Quality evaluation of #diabetescare can be improved significantly by aligning these indicators between registries.   https://lnkd.in/eqNdvMSd   #Diabetesregistry #Qualityindicators #DPARD

NEW Diabeter publication: The ‘Biomarkers of heterogeneity in type 1 diabetes’ study – a national prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes in the Netherlands. BMJ Open 2024 Jun 19;14(6):e082453   There is extensive heterogeneity between people with #type1diabetes (PWDs) in terms of clinical symptoms at onset, autoimmune markers, initial glycemic outcomes and the efficacy of therapeutic interventions. Understanding this heterogeneity, including factors influencing complications and quality of life, is essential for developing personalized interventions and improving outcomes. The decline in insulin-producing #betacell function is progressive, going through four stages: two pre-symptomatic stages (1 and 2), followed by the onset of clinical symptoms (Stage 3), and long-standing T1D (Stage 4). Many studies on heterogeneity include PWDs in stages 1-3. The "#Biomarkers of #heterogeneity in type 1 diabetes" study, co-authored by Diabeter authors, aimed to explore heterogeneity among PWDs with stage 4 T1D. Initial results included:   ·        Association of residual #Cpeptide secretion with a lower risk of impaired awareness of #hypoglycemia (IAH) ·        Differentially expressed metabolites between PWDs with and without IAH ·        C-peptide (as proxy for insulin production) could still be induced in 10% of PWDs who had non-detectable fasting C-peptide levels   Please look here for more information: https://lnkd.in/evzRneRe   #diabetes #diabetesresearch #diabetescomplications #type1diabetescomplications #hypocompass #impairedawareness

Impaired awareness of #hypoglycemia (#IAH), the inability to detect the onset of hypoglycemia, is a serious consequence of long-term #T1D. IAH is associated with higher risk of asymptomatic and severe hypoglycemia and a lower quality of life. Signaling and metabolic pathways involved in the counter-regulatory response to hypoglycaemia are currently not well-understood, but are suggested to result in adaptive changes in the brain, leading to IAH. In this publication, co-authored by Henk-Jan Aanstoot and Dick Mul of Diabeter, #metabolomics and genome-wide association (#GWA) methodologies were combined to look for metabolites that are expressed differentially between people with type 1 diabetes (PWDs) with IAH and PWDs without IAH. A number of metabolites were identified that showed higher expression in PWDs with IAH.   Please look here for more information: https://lnkd.in/eqcxXCXd   #diabetes #diabetesresearch #type1diabetes #diabetescompications #type1diabetescomplications #hypocompass #impairedawareness 

Type 1 and 2 diabetes pose a significant global #healthcare challenge, impacting over 529 million individuals and costing nearly $966 billion. Health disparities persist among various demographics, particularly regarding socio-economic status (#SES). A study in the Netherlands investigated the relationship between SES and hospital resource use for diabetes patients. Findings reveal that individuals with low SES experience higher #hospitalization rates, less #technology usage, and more #complications, underscoring the need for targeted interventions to ensure equitable diabetes care, especially in children. Please look here for more information: https://lnkd.in/dTeTznRm #diabetes #type1diabetes #type 2 diabetes #socioeconomicstatus #diabetestechnology

Providing optimal pediatric care for #T1D poses challenges due to varying #caresystems across Europe, highlighting the importance of centralized care models and #multidisciplinary approaches. This paper, co-authored by #Diabeter authors Theo Sas and Dick Mul, assesses possible associations between hospital volumes and resource use for T1D care. Findings reveal variations in #hospitalizations, consultations, and expenditures across different hospital sizes, indicating a need for further research on possible effects on clinical outcomes. Please look here for more information: https://lnkd.in/egetpwNa #type1diabetes #healthcarecosts #healtheconomics #hecon #hospitalcosts #valuebasedcare

Earlier we reported publication of the first results of the #Diagnode-1 and Diagnode-2 studies, in which Diabeter was a participating center, testing Diamyd Medical’s diabetes vaccine #GAD-alum (#Diamyd ®) in people with recently diagnosed #T1D (<6 months). In these studies especially people with the HLA DR3-DQ2 haplotype showed improved glycemic control after treatment with Diamyd. Diamyd Medical is now recruiting people with recently diagnosed T1D and with the HLA DR3-DQ2 haplotype for the Diagnode 3 study, in which Diabeter is again participating center. Please look here for more information: https://lnkd.in/e4vVCnvt   #type1diabetes #glycemiccontrol #Diagnode #Diamyd #diabetesvaccine #DR3-DQ2